Sep 29, 2010:
iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
Sep 22, 2010:
iCo Therapeutics Appoints Infectious Disease Experts to Scientific Advisory Board
Aug 27, 2010:
iCo Therapeutics Announces Second Quarter 2010 Financial Results
Jul 26, 2010:
iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-007
May 28, 2010:
iCo Therapeutics Inc. enters into Investor Relations Engagements with The Trout Group and Sector Speak
May 26, 2010:
iCo Therapeutics Announces First Quarter 2010 Financial Results
May 25, 2010:
iCo Therapeutics Inc. enters into Technology Transfer Agreement with Isis Pharmaceuticals, Inc. for iCo-007
May 17, 2010:
iCo Therapeutics iCo-007 Phase I Clinical Trial Meets Primary Endpoint
Apr 29, 2010:
iCo Therapeutics Announces Year-End 2009 Financial Results
Apr 28, 2010:
iCo Therapeutics Inc. engages Susan Koppy to spearhead iCo-007 out-licensing
Apr 22, 2010:
iCo-007 for Diffuse Diabetic Macular Edema to be Presented at Retinal Physician Symposium 2010
Apr 12, 2010:
iCo Therapeutics Inc. Recognized by BIOTECanada with Gold Leaf Award
Feb 19, 2010:
iCo-007 for Diabetic Macular Edema to be Presented at Angiogenesis 2010: Clinical Trials
Feb 10, 2010:
iCo Therapeutics Announces Exercise of Warrants